Login to Your Account

Clinic Roundup

Monday, April 23, 2012

• Bristol-Myers Squibb Co., of New York, reported at the European Association for the Study of the Liver meeting in Berlin, that in a Phase II trial of daclatasvir and asunaprevir in difficult-to-treat genotype 1b hepatitis C patients, 77 percent of subjects achieved undetectable viral load at 24 weeks post-treatment (SVR24).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription